Over the 90-day window ending February 19, 2026, Roivant Sciences's three dominant insider ownership positions are held by TenPercentOwner Pharma Technologies Ltd. Dexcel (102.85Mn shares), TenPercentOwner Investments (Uk) Ltd Svf (73.03Mn shares), TenPercentOwner Chemical Co., Ltd. Sumitomo (71.25Mn shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Pharma Technologies Ltd. Dexcel | 102,849,443 | 14 Nov, 2022 | |
| Investments (Uk) Ltd Svf | 73,031,667 | 02 Oct, 2023 | |
| Chemical Co., Ltd. Sumitomo | 71,251,083 | 26 Jun, 2023 | |
| Vivek Ramaswamy | 47,011,612 | 15 Dec, 2025 | |
| Daniel Allen Gold | 24,093,223 | 12 Sep, 2025 | |
| Mayukh Sukhatme | President & Cio | 18,836,547 | 11 Feb, 2026 |
| Matthew Gline | Ceo | 17,287,081 | 17 Dec, 2025 |
| Keith S Manchester | 17,075,732 | 12 Sep, 2025 | |
| Financial Lp Qvt | 15,127,329 | 13 Feb, 2026 | |
| Frank Torti | President And Vant Chair | 13,736,547 | 29 Dec, 2025 |
| Global Investors Lp Viking | 12,884,307 | 26 Jun, 2023 | |
| Global Performance Llc Viking | 12,884,307 | 26 Jun, 2023 | |
| Eric Venker | President & Immunovant Ceo | 1,654,597 | 14 Jan, 2026 |
| Richard Pulik | Cfo | 239,413 | 29 Dec, 2025 |
| Rakhi Kumar | Chief Accounting Officer | 162,306 | 24 Feb, 2025 |
| Ilan Oren | 119,428 | 22 Jan, 2026 | |
| Jennifer Humes | Chief Accounting Officer | 112,255 | 24 Mar, 2025 |
| James C Momtazee | 109,030 | 22 Jan, 2026 | |
| Melissa B, Epperly | 57,665 | 22 Jan, 2026 | |
| Andrew Lo | 52,142 | 19 Sep, 2022 | |
| Meghan Fitzgerald | 42,963 | 12 Sep, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 13 Feb, 2026 | Keith S Manchester | Common Shares | D | 150,784 | $26.49 | 15,352,329 | I | S |
| 13 Feb, 2026 | Keith S Manchester | Common Shares | D | 225,000 | $26.50 | 15,127,329 | I | S |
| 13 Feb, 2026 | Financial Lp Qvt | Common Shares | D | 150,784 | $26.49 | 15,352,329 | I | S |
| 13 Feb, 2026 | Financial Lp Qvt | Common Shares | D | 225,000 | $26.50 | 15,127,329 | I | S |
| 13 Feb, 2026 | Daniel Allen Gold | Common Shares | D | 150,784 | $26.49 | 15,352,329 | I | S |
| 13 Feb, 2026 | Daniel Allen Gold | Common Shares | D | 225,000 | $26.50 | 15,127,329 | I | S |
| 12 Feb, 2026 | Keith S Manchester | Common Shares | D | 150,000 | $26.72 | 15,778,113 | I | S |
| 12 Feb, 2026 | Keith S Manchester | Common Shares | D | 275,000 | $26.76 | 15,503,113 | I | S |
| 12 Feb, 2026 | Financial Lp Qvt | Common Shares | D | 150,000 | $26.72 | 15,778,113 | I | S |
| 12 Feb, 2026 | Financial Lp Qvt | Common Shares | D | 275,000 | $26.76 | 15,503,113 | I | S |
| 12 Feb, 2026 | Daniel Allen Gold | Common Shares | D | 275,000 | $26.76 | 15,503,113 | I | S |
| 12 Feb, 2026 | Daniel Allen Gold | Common Shares | D | 150,000 | $26.72 | 15,778,113 | I | S |
| 11 Feb, 2026 | Keith S Manchester | Common Shares | D | 425,000 | $26.67 | 15,928,113 | I | S |
| 11 Feb, 2026 | Financial Lp Qvt | Common Shares | D | 425,000 | $26.67 | 15,928,113 | I | S |
| 11 Feb, 2026 | Daniel Allen Gold | Common Shares | D | 425,000 | $26.67 | 15,928,113 | I | S |
| 09 Feb, 2026 | Mayukh Sukhatme | Common Shares | D | 312,117 | $26.47 | 18,836,547 | D | J |
| 09 Feb, 2026 | Mayukh Sukhatme | Common Shares | A | 651,558 | $12.68 | 19,488,105 | D | M |
| 09 Feb, 2026 | Mayukh Sukhatme | Common Shares | D | 339,441 | $26.47 | 19,148,664 | D | S |
| 20 Jan, 2026 | James C Momtazee | Common Shares | A | 609 | $0.00 | 109,152 | D | A |
| 20 Jan, 2026 | James C Momtazee | Common Shares | D | 122 | $22.98 | 109,030 | D | F |